Reviewing Pieris Pharmaceuticals Inc. (PIRS)’s and CEL-SCI Corporation (NYSEAMERICAN:CVM)’s results

Both Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) and CEL-SCI Corporation (NYSEAMERICAN:CVM) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.

Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pieris Pharmaceuticals Inc. 42.34M 3.67 7.58M -0.13 0.00 CEL-SCI Corporation N/A 179.26 31.85M -1.72 0.00 Demonstrates Pieris Pharmaceuticals Inc. and CEL-SCI Corporation earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 shows Pieris Pharmaceuticals Inc. and CEL-SCI Corporation’s return on assets, return on equity and net margins. Net Margins Return on Equity Return on Assets Pieris Pharmaceuticals Inc. -17.90% -18.1% -5.1% Volatility and Risk

Pieris Pharmaceuticals Inc.’s current beta is 1.82 and it happens to be 82.00% more volatile than S&P 500. Competitively, CEL-SCI Corporation’s beta is 0.84 which is 16.00% less volatile than S&P 500.

Liquidity

The Current Ratio and Quick Ratio of Pieris Pharmaceuticals Inc. are 3.6 and 3.6 respectively. Its competitor CEL-SCI Corporation’s Current Ratio is 0.4 and its Quick Ratio is 0.3. Pieris Pharmaceuticals Inc. can pay off short and long-term obligations better than CEL-SCI Corporation.

Insider & Institutional Ownership

Roughly 66.9% of Pieris Pharmaceuticals Inc. shares are owned by institutional investors while 6.6% of CEL-SCI Corporation are owned by institutional investors. Insiders owned 0.21% of Pieris Pharmaceuticals Inc. shares. Insiders Comparatively, owned 5.6% of CEL-SCI Corporation shares.

Performance

Here are the Week, Month, Quarter, Half Year, Year and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Pieris Pharmaceuticals Inc. 1.77% -8.97% -34.91% -40.82% -43.81% -54.3% CEL-SCI Corporation -3.66% -0.32% -18.56% 13.67% 79.55% 67.21% For the past year Pieris Pharmaceuticals Inc. had bearish trend while CEL-SCI Corporation had bullish trend.

Summary

Pieris Pharmaceuticals Inc. beats CEL-SCI Corporation on 5 of the 9 factors.

Pieris Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops Anticalin-based drugs. It develops Anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company primarily focuses on the development of four drug candidates, including PRS-080 designed to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; PRS-060, a drug candidate that binds to the IL-4RA receptor alpha-chain, which is used for the treatment of asthma and other inflammatory diseases; PRS-343, a bispecific protein for oncology diseases; and PRS-332, a bispecific anticalin-antibody fusion protein for oncology diseases. It has strategic partnership agreements with Allergan, Inc.; Sanofi Group; Daiichi Sankyo Company Limited; F.Hoffmann- La Roche Ltd. and Hoffmann- La Roche Inc.; ASKA Pharmaceutical Co., Ltd; and Les Laboratoires Servier and Institut de Recherches Internationales. The company also has a research and licensing agreement with Technische Universität München; and a collaboration agreement with AstraZeneca. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

CEL-SCI Corporation engages in the research and development of drugs and vaccines. Its lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. The companyÂ’s Multikine is also used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *